ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting

    Physical Function Trajectories in Children with Juvenile Myositis

    Kaveh Ardalan1, Elizabeth L. Gray2, Julia (Jungwha) Lee2, Madison L. Wolfe3, Gabrielle A. Morgan4 and Lauren M. Pachman5, 1Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Creighton University School of Medicine, Omaha, NE, 4Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…
  • Abstract Number: 1852 • 2018 ACR/ARHP Annual Meeting

    Pregnancy in Lupus: 17-Year U.S. Nationwide Trend in Obstetric and Maternal Outcomes

    Yiming Luo1, Jiehui Xu2 and Bella Y. Mehta3,4, 1Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, 2Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, 3Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, 4Patient Oriented Research Program, Columbia University Mailman School of Public Health, New York, NY

    Background/Purpose: Pregnancies in systemic lupus erythematosus (SLE) are considered high risk and associated with medical and obstetric complications [1]. Our objective was to study the…
  • Abstract Number: 1853 • 2018 ACR/ARHP Annual Meeting

    Paternal Use of Methotrexate (MTX) and Congenital Malformations – a Systematic Review and Meta-Analysis

    Thomas Bo Jensen1, Mikkel Bring Christensen1,2 and Jon Trærup Andersen1,2, 1Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark, 2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: In rheumatology, fertile men and women are commonly treated with methotrexate (MTX). Maternal preconceptional MTX exposure is teratogenic, but less is known about paternal…
  • Abstract Number: 1854 • 2018 ACR/ARHP Annual Meeting

    SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates

    Julia Davis-Porada1, Sam Stern2, Marta M. Guerra3, Carl Laskin4,5, Michelle Petri6, Michael Lockshin7, Lisa R Sammaritano8,9, David Branch10,11, Allen D. Sawitzke12, Joan T. Merrill13,14, Jill P. Buyon15, Mimi Kim16 and Jane E. Salmon8,9, 1Research, Hospital for Special Surgery, New York, NY, 2Albert Einstein College of Medicine, New York, NY, 3Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, 4Mount Sinai Hospital Toronto, Toronto, ON, Canada, 5Trio Fertility, Toronto, ON, Canada, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Barbara Volcker Center, Hospital for Special Surgery, New York, NY, 8Hospital for Special Surgery, New York, NY, 9Weill Cornell Medicine, New York, NY, 10Intermountain Healthcare, Salt Lake City, UT, 11Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, 12Rheumatology, University of Utah Health Sciences Center, Salt Lake City, UT, 13University of Oklahoma Health Sciences Center, Oklahoma City, OK, 14Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Medicine, New York University School of Medicine, New York, NY, 16Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects women of childbearing age. Low disease activity for 6 months prior to conception leads to the best outcomes;…
  • Abstract Number: 1855 • 2018 ACR/ARHP Annual Meeting

    Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus

    Jill P. Buyon1, Peter M. Izmirly2, H. Michael Belmont3, John Conklin4, Nicole Kaiden5, Jane E. Salmon6, Roberta Alexander4 and Thierry Dervieux4, 1Medicine, New York University School of Medicine, New York, NY, 2NYU Langone Health, New York, NY, 3Medicine, NYU Langone Health, New York, NY, 4Exagen Diagnostics, Inc., Vista, CA, 5Medicine, NYU School of Medicine, New York, NY, 6Medicine/Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Activation of the alternative and terminal attack complex of the complement system has been associated with adverse pregnancy outcomes (APOs) in stable/quiescent systemic lupus…
  • Abstract Number: 1856 • 2018 ACR/ARHP Annual Meeting

    Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort

    Arielle Mendel, Sasha Bernatsky and Evelyne Vinet, Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Because aspirin reduces the risk of preeclampsia in high-risk pregnancies by more than half, best practice guidelines recommend that aspirin be initiated in pregnant…
  • Abstract Number: 1857 • 2018 ACR/ARHP Annual Meeting

    Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss

    Meiying Wang1,2, Peng Zhang3, gengmin zhou1, jiyang lv1, chengshan guo4 and Qingwen Wang1, 1Rheumatology and Immunology, Peking University Shenzhen Hospital, shenzhen, China, 2Rheumtology, David Geffen school of Medicine at UCLA, Los Angeles, CA, 3SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES, shenzhen, China, 4Rheumatology and Immunology, The people's Hospital of Bao’an District Shenzhen City., shenzhen, China

    Background/Purpose: Type 1/type 2 T helper (Th1/Th2) cells and their cytokines are implicated in the pathogenesis of autoimmune diseases[1]; however, their roles in antiphospholipid antibody-associated…
  • Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting

    An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis

    Thierry Dervieux1, Laura Martinez Prat2, John Conklin1, Claudia Ibarra1, Michael Mahler2, Michael E Weinblatt3 and Joel Kremer4, 1Exagen Diagnostics, Inc., Vista, CA, 2Research and Development, Inova Diagnostics, San Diego, CA, 3Brigham and Women's Hospital, Boston, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
  • Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting

    The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Alexander Platzer2, Farideh Alasti2, Paul Studenic3, Maresa Grundhuber4, Sascha Swiniarski4, Stephan Blüml2, Helmuth Haslacher5, Josef S. Smolen6 and Günter Steiner1, 1Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, 2Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, 5Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, 6Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
  • Abstract Number: 1860 • 2018 ACR/ARHP Annual Meeting

    Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects

    Michelle J. Ormseth, Joseph F. Solus, Quanhu Sheng, Fei Ye, Qiong Wu, Yan Guo, Annette M. Oeser, Ryan Allen, Kasey Vickers and C Michael Stein, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes and have utility as disease biomarkers. Use of small RNA (sRNA) sequencing along with unbiased…
  • Abstract Number: 1861 • 2018 ACR/ARHP Annual Meeting

    Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis

    Nikila Kumar1, Wei-Hsuan Lo-Ciganic2, Lili Zhou3,4, Erin L. Ashbeck4 and C. Kent Kwoh1,4, 1Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, 2Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, 3College of Pharmacy, University of Arizona, Tucson, AZ, 4University of Arizona Arthritis Center, Tucson, AZ

    Background/Purpose: Patients with RA have an increased risk of cardiovascular disease (CVD) accounting for over 50% of premature deaths in the RA population. EULAR recommends…
  • Abstract Number: 1862 • 2018 ACR/ARHP Annual Meeting

    Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers

    Jon T. Giles1, Cecilia P. Chung2, Mary Chester-Wasko3, Mike Centola4, Jenny Van Eyk5, Justyna Fert-Bober5, Amy Kao6, Annette M. Oeser7, C. Michael Stein2 and Joan Bathon8, 1Medicine/Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Allegheny Health Network, Pittsburgh, PA, 4Haus Bioceuticals, Inc, Oklahoma City, OK, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6Biogen, Cambridge, MA, 7Vanderbilt University Medical Center, Nashville, TN, 8Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) patients with very low levels of circulating low density lipoprotein cholesterol (LDL-C) have been reported to be at particularly high risk…
  • Abstract Number: 1863 • 2018 ACR/ARHP Annual Meeting

    Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years

    Leah F. Bettner1, Lindsay B. Kelmenson1, M. Kristen Demoruelle1, Ted R. Mikuls2, Jess Edison3, Elizabeth A. Mewshaw4, Mark C. Parish1, Marie L. Feser1, Ashley A. Frazer-Abel1, LauraKay Moss1, Michael Mahler5, V. Michael Holers6 and Kevin D. Deane1, 1Division of Rheumatology, University of Colorado Denver, Aurora, CO, 2Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 4Walter Reed National Military Medical Center, Bethesda, MD, 5Research and Development, Inova Diagnostics, San Diego, CA, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Serum elevations of antibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF) can identify individuals at risk for developing rheumatoid arthritis (RA). Prior…
  • Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting

    Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

    Désirée van der Heijde1, James Cheng-Chung Wei2, Maxime Dougados3, Philip J. Mease4, Atul A. Deodhar5, Walter P. Maksymowych6, Filip van Den Bosch7, Joachim Sieper8, Tetsuya Tomita9, Robert B.M. Landewé10, Lotus Mallbris11, Fangyi Zhao11, David Adams11, Beth Pangallo11 and Hilde Carlier11, 1Leiden University Medical Centre, Leiden, Netherlands, 2Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, 3Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, 4Swedish Medical Center and University of Washington, Seattle, WA, 5Oregon Health & Science U, Portland, OR, 6University of Alberta, Edmonton, AB, Canada, 7Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 8Charité University Hospital, Berlin, Germany, 9Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, 10Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 11Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
  • Abstract Number: 1865 • 2018 ACR/ARHP Annual Meeting

    Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active As/Radiographic Axial Spa Naive to Biologic DMARD Therapy: 16‑Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

    Uta Kiltz1, Désirée van der Heijde2, Annelies Boonen3,4, Lianne S. Gensler5, Theresa Hunter6, Fangyi Zhao6, Hilde Carlier6 and Jürgen Braun1,7, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Leiden University Medical Centre, Leiden, Netherlands, 3Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 4Caphri Research Institute, Maastricht, Netherlands, 5School of Medicine, UCSF, San Francisco, CA, 6Eli Lilly and Company, Indianapolis, IN, 7Ruhr Universität Bochum, Bochum, Germany

    Background/Purpose: The Assessment of SpA international Society Health Index (ASAS HI) is a relatively new measure to assess function, disability, and health in patients with…
  • « Previous Page
  • 1
  • …
  • 1126
  • 1127
  • 1128
  • 1129
  • 1130
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology